Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Teratogenesis A “teratogen”, from the Greek root teras, meaning monster or marvel, is any environmental factor that causes a structural or functional abnormality in the developing fetus or embryo. These environmental agents include infections, medications, drugs, chemicals, maternal metabolites, such as phenylalanine or mechanical forces.(1-2) Effects of drugs on the fetus (2) the first week after fertilization is the “period of the zygote”. During this time the most common adverse effect of drugs is the termination of pregnancy , which may occur before the woman even knows that she is pregnant. The second to the eighth week of gestation is “period of the embryo”. It is mainly during this period of organogenesis that drugs produce dramatic and catastrophic structural malformations. terminology Malformation(3) A primary structural defect arising from a localized error in morphogenesis. (cardiac septal defects) Deformation An alteration in shape or structure of a part that has differentiated normally. (mostly involving musculoskeletal system and are probably caused by intrauterine molding, like various forms of clubfoot and congenital hip dislocation) Disruption A structural defect resulting from destruction of a previously normally formed part. two mechanisms are involved: 1-entanglement followed by tearing apart or amputation (like amniotic bands) 2-interruptioin of blood supply to a developing part, leading to infarction, necrosis or resorption of structure distal to the insult. (like jejunoileal atresia and gastroschisis) Dysplasia An abnormal organization of cells and the structural consequences. ( localized like hemangioma, generalized like connective tissue disorders) drug Effect on fetus and neonate Accutane ) isotretinoin ) Facial-ear anomaly, heart defect, CNS anomaly alcohol Congenital cardiac, CNS, limb anomalies carbamazepine Spina bifida Carbon monoxide Cerebral atrophy, microcephaly, seizure Cocaine/crack Microcephaly, LBW, IUGR misoprostol Arthrogryposis, cranial neuropathies, equinovarus phenytoin neuroblastoma Warfarin (coumadin) Fetal bleeding and death, hypoplastic nasal structures penicillamine Cutis laxa syndrome MATERNAL MEDICATION AND TOXIN EXPOSURE AND THE FETUS(3) The effects of drugs taken by the mother vary considerably, especially in relation to the time in pregnancy when they are taken and the fetal genotype for drug metabolizing enzymes. Miscarriage or congenital malformations result from the maternal ingestion of teratogenic drugs during the period of organogenesis. Maternal medications taken later, particularly during the last few weeks of gestation or during labor, tend to affect the function of specific organs or enzyme systems, and they adversely affect the neonate rather than the fetus . Diagnosis time The effects of drugs may be evident immediately in the delivery room or later in the neonatal period, or they may be delayed even longer. The administration of diethylstilbestrol during pregnancy has resulted in vaginal adenosis and vaginal adenocarcinoma in females in the 2nd or 3rd decade. In addition to in utero carcinogenesis, various reproductive problems have been reported in these women, including cervical anomalies and premature births, ectopic pregnancies, and spontaneous pregnancy loss. Impact of genetic Evidence has confirmed an interaction between genetic factors and susceptibility to certain drugs or environmental toxins. •Phenytoin teratogenesis may be mediated by genetic differences in the enzymatic production of epoxide metabolites; specific genes may influence the adverse effects of benzene exposure during pregnancy. •Growth-restricting effects of smoking on the fetus is influenced by polymorphisms of genes encoding enzymes that metabolize the polycyclic aromatic hydrocarbons in cigarette smoke . Drug use in pregnancy Often the risk of controlling maternal disease must be balanced with the risk of possible complications in the fetus. The majority of women with epilepsy have normal fetuses. Nonetheless, several commonly used antiepileptic drugs (AEDs) are associated with congenital malformations. Infants exposed to valproic acid may have multiple anomalies including neural tube defects, hypospadias, facial anomalies, cardiac anomalies, and limb defects. In addition, they have lower developmental index scores compared to those unexposed infants or those exposed to other commonly used AED. Radiation(3) Accidental exposure of pregnant women to radiation is a common cause for anxiety about whether the fetus will have birth defects or genetic abnormalities. It is unlikely that exposure to diagnostic radiation will cause gene mutations; no increase in genetic abnormalities has been identified in the offspring exposed as unborn fetuses to the atomic bomb explosions in Japan in 1945. Maximum safe dose of radiation in pregnancy The recommended occupational limit of maternal exposure to radiation from all sources is 500 mrad for the entire 40 wk of a pregnancy. The limited data on human fetuses show that large doses of radiation (20,000-50,000 mrad) are harmful to the central nervous system, as evidenced by microcephaly, mental retardation, and IUGR. Leukemia is another risk. Therapeutic abortion is often recommended when exposure exceeds 10,000 mrad. It is more likely that a human fetus will be exposed to 1,0003,000 mrad, an amount not shown to cause malformations. Whether this level of fetal exposure is associated with an increased risk for childhood cancer or leukemia is controversial. Maternal PKU Mental retardation, hypertonia, low birth weight, microcephaly, cardiac defects, spontaneous abortion. Multiple malformation vs sequence The pattern of multiple anomalies that occurs when a single primary defect in early morphogenesis produces multiple abnormalities through a cascading process of secondary and tertiary errors in morphogenesis is called a sequence. When evaluating a child with multiple anomalies, the physician must differentiate multiple anomalies secondary to a single localized error in morphogenesis (a sequence) from a multiple malformation syndrome. In the former, recurrence risk counseling for the multiple anomalies depends entirely on the risk of recurrence for the single localized malformation. The Robin malformation sequence is a pattern of multiple anomalies produced by mandibular hypoplasia. Because the tongue is relatively large for the oral cavity, it drops back (glossoptosis), blocks closure of the posterior palatal shelves, and causes a V-shaped cleft palate. There are numerous causes of mandibular hypoplasia, all of which result in characteristic features of Robin sequence. Fetal alcohol syndrome 1. 2. 3. 4. 5. Prenatal onset and persistence of growth deficiency for weight, length, and head circumference. Facial abnormalities including short palpebral fissure, epicanthal folds, maxillary hypoplasia, micrognathia, and thin upper lips. Cardiac defects, primarily septal defects. Minor joint and limb abnormalities including some restriction in movements and altered palmar crease pattern. Delayed development and mental deficiency varying from borderline to severe. Cigarette smoking Low birth weight danazole virilization hyperthermia Spina bifida lithium Ebstein’s anomaly, macrosomia methyltestosterone Masculinization of female fetus Methyl mercury Minamata disease Prednisolone Cleft palate and lip progesterone Masculinization of female fetus Vitamin D Supravalvular aortic stenosis, hypercalcemia misoprostol Arthrogryposis, cranial neuropathies amiodarone Bradycardia, hypothyroidism Anesthetic agents (volatile) CNS depression Aspirin Neonatal bleeding Captopril Transient anuric renal failure, oligohydramnios Dexamethasone Periventricular leukomalacia fluoxetine Transient neonatal withdrawal, hypertonicity Oxytocin Hyperbilirubinemia, hyponatremia isoxsuprine Ileus, hypoglycemia, hypocalcemia, hypotension Pyridoxine seizure sulfonylurea Refractory hypoglycemia References 1. Avery 2005 2. Fanarof 2006 3. Nelson 2004